Fig. 2

Statistics on the occurrence of severe cardiac adverse events in anti-PD-1/PD-L1 reports from the FAERS database during 2014–2022. (A) The upper bar plot shows the number of anti-PD-1/PD-L1 reports with cardiac adverse events versus anti-PD-1/PD-L1 reports without cardiac adverse events in the FAERS database during 2014 and 2022, as well as the overall situation. The proportional bar plot below shows the number of anti-PD-1/PD-L1 reports with cardiac adverse events versus anti-PD-1/PD-L1 reports without cardiac adverse events in the FAERS database during 2014 and 2022, as well as the overall situation. (B) The upper bar plot shows the number of anti-PD-1/PD-L1 reports with cardiac adverse events versus anti-PD-1/PD-L1 reports without cardiac adverse events for different anti-PD-1/PD-L1 treatment strategies in the FAERS database from 2014 to 2022 and the overall situation. The proportional bar plot below shows the amount of anti-PD-1/PD-L1 reports with cardiac adverse events versus anti-PD-1/PD-L1 reports without cardiac adverse events for different anti-PD-1/PD-L1 treatment strategies in the FAERS database from 2014 to 2022 and overall situation. AEs: adverse events.